Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in...

cafead

Administrator
Staff member
  • cafead   Aug 31, 2022 at 10:22: PM
via Additional one-year data continue to show rapid and sustained normalization to healthy levels of CSF heparan sulfate and improvements in biomarkers of lysosomal function consistent with durable central nervous system activity

article source
 

<